MLN0128 (formerly known as INK128) is a novel, orally active mTOR kinase inhibitor currently in clinical development. Here, we evaluated MLN0128 in preclinical models of B-cell acute lymphoblastic ...

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine ... cells and will help in the selection and validation of new small-molecule inhibitors of ALK. Identification of oncogenic ALK genomic ...

1Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate ...

Dr. Salvador, together with Dr. Claudia Valverde, from Vall d'Hebron Hospital, facilitated access to new inhibitors, which are currently undergoing testing in clinical environments. Additionally ...

However, the clinical efficacy of mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) for MAP2K1-mutant tumors is not well defined. We sought to characterize the genomic and clinical ...